Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Entera Bio Ltd., a foreign private issuer, for the month of June 2021. The filing date is June 17, 2021. The report consists solely of a press release issued on the same date, which is attached as Exhibit 99.1 and incorporated by reference into the company's registration statements on Form F-3.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a vehicle to distribute a press release and does not contain audited financial statements or a management discussion and analysis of financial condition.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The content is limited to the incorporation of a press release without specific comparative financial data within the Form 6-K text itself.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. While the referenced press release likely contains such information, the specific details are not present in the provided Form 6-K text.
Key Facts for Investors to Verify
- Review the attached Exhibit 99.1 (Press Release dated June 17, 2021) for the specific operational or clinical updates intended by this filing.
- Verify the incorporation of this report into Registration Statements 333-238988 and 333-239843.
- Confirm the company's status as a registrant filing under Form 20-F.
- Note that no financial data is disclosed directly within this Form 6-K document.